Drug Trial Radar · NCT01869725
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
Last checked: Nov 20, 2026Latest source record: Sep 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Apr 1, 2013
Primary completion
Dec 26, 2018
Study completion Dec 26, 2018
Sponsor
- Lead sponsor
- Sue O'DorisioAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Jun 5, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging of patients with neuroendocrine tumors.
Conditions
- Adult Medulloblastoma
- Childhood Medulloblastoma
- Neuroblastoma
- Neuroendocrine Tumor
- Somatostatinoma
Interventions
gallium Ga 68-edotreotideDrug
Given IV
positron emission tomography/computed tomographyProcedure
Undergo gallium Ga 68-edotreotide PET/CT scan
indium In 111 pentetreotideRadiation
Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
computed tomographyProcedure
Undergo indium In 111 pentetreotide contrast-enhanced CT scan
contrast-enhanced magnetic resonance imagingProcedure
Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of Conventional Imaging and Gallium Ga 68-edotreotide PET Using Concordance in Tumor Detection With PathologyTime frame: Up to 6 months between the timing of the Octreoscan SPECT/CT plus high-resolution, contrast-enhanced CT and the time of the 68Ga-DOTATOC PET/CT (either imaging type may occur first)
- Compare Sensitivity of 68Ga-DOTATOC PET/CT With OctreoscanTime frame: Up to 6 months
- Compare Specificity of 68Ga-DOTATOC PET/CT With OctreoscanTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.